Keurig Dr Pepper Inc. Common Stock vs State Street SPDR S&P Biotech ETF — how do they compare? Keurig Dr Pepper Inc. Common Stock trades at $31.76 (market cap $42.54B), while State Street SPDR S&P Biotech ETF trades at $153.75 (market cap $10.11B). The key difference: Keurig Dr Pepper Inc. Common Stock is far larger — about 4.2× State Street SPDR S&P Biotech ETF's market cap, and Keurig Dr Pepper Inc. Common Stock pays a 2.94% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Keurig Dr Pepper Inc. Common Stock for 1 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| KDP | XBI | |
|---|---|---|
Market Cap | $42.54B | $10.11B |
Volume | 14,530,234 | 12,903,266 |
Sector | Consumer Staples | Broad Market / Factor |
52-Week High | $33.50 | $169.55 |
52-Week Low | $25.31 | $104.99 |
Typical Hold Time | 1 Days | 38 Days |
Enterprise Value | $71.00B | — |
Dividend Yield | 2.94% | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
XBI trades at $149.29, down 0.63% on the day, with technical indicators showing a bearish bias despite oversold RSI conditions. The ETF faces mixed sentiment with 100% hold ratings from analysts but positive catalysts from biotech breakthroughs. Recent news highlights XBI's 76% rally over the past year and ongoing M&A activity driving sector optimism.
Outlook remains cautiously optimistic with potential upside from cancer vaccine developments and sector consolidation, though high volatility and expense ratios relative to broader healthcare ETFs present risks. The ETF's modified equal-weight structure offers diversified exposure to 150+ biotech names, benefiting from improved capital access and clinical trial catalysts.
Trailing returns across standard periods
Latest headlines on both assets
Keurig Dr Pepper produces and distributes coffee, soft drinks, juices, and other beverages. It also operates the Keurig single-serve coffee system.
Read more on KDP →XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →